Trump’s Obesity Drug Plan Faces Scrutiny

The Trump administration's plan to offer GLP-1 weight-loss drugs under Medicare at a reduced rate of $50 per month is set to begin on July 1. Critics argue that the temporary nature of this program may be difficult to terminate, raising concerns about long-term healthcare policies.